Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective hard but unsuccessfully to develop an one off therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination therapy in the healing of multi-drug-resistant HIV happen to be closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my past few shares. The 1st CytoDyn article of mine, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set away what follows prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such a highly marketing picture in the Uptick Newswire employment interview that I came away with a poor impression of the business.

Irony of irony, the bad viewpoint of mine of the business has grown steadily, though the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger at the moment still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall refer to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your therapy as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of this expertise and associated intellectual property coming from Progenics to CytoDyn, and also approximately twenty five million mg of majority drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 huge number of) and also the first brand new drug program endorsement ($five million), and even royalty payments of five percent of net sales upon commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous therapies and multiple indications, it has this single treatment as well as a “broad pipeline of indications” since it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially advantageous therapy of dozens of indications.

The opening banner of its on its site (below) shows an energetic organization with diverse interests albeit focused on leronlimab, multiple disease types, multiple publications and multiple presentations.

Might all of it be smoke cigarettes and mirrors? That’s a question I have been asking myself with the very beginning of my interest in this particular organization. Judging by the multiples of thousands of diverse responses on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I am a lot from alone in this particular question.

CytoDyn is a classic battleground, or maybe some may say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *